24131-32-6

Basic information

• Product Name: 3,5-BIS(BENZYLOXY)BENZYL BROMIDE
• Synonyms: 5-BROMOMETHYLRESORCINOL DIBENZYL ETHER;3,5-BIS(BENZYLOXY)BENZYL BROMIDE;3,5-DIBENZYLOXY-ALPHA-BROMOTOLUENE;3,5-DIBENZYLOXYBENZYL BROMIDE;3,5-DIBENZYLOXYBENZYL BROMIDE 98+%;Benzene,1-(bromomethyl)-3,5-bis(phenylmethoxy)-;3,5-Bis(benzyloxy)benzyl Bromide 3,5-Dibenzyloxy-alpha-bromotoluene;(((5-(bromomethyl)-1,3-phenylene)bis(oxy))bis(methylene))dibenzene
• CAS NO: 24131-32-6
• Molecular Formula: C₂₁H₁₉BrO₂
• Molecular Weight: 383.28
• Product Categories: Building Blocks for Dendrimers;Functional Materials
• Mol File: 24131-32-6.mol
• Article Data: 33

Chemical Properties

• Melting Point: 86-88
• Boiling Point: 504.3°C at 760 mmHg
• Flash Point: 209.8°C
• Appearance: /
• Density: 1.329±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 8.44E-10mmHg at 25°C
• Refractive Index: 1.619
• Storage Temp.: Refrigerator
• CAS DataBase Reference: 3,5-BIS(BENZYLOXY)BENZYL BROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-BIS(BENZYLOXY)BENZYL BROMIDE(24131-32-6)
• EPA Substance Registry System: 3,5-BIS(BENZYLOXY)BENZYL BROMIDE(24131-32-6)

Safety Data

• Hazard Codes: Xi
• RIDADR: UN 1759 8/PG III
• HazardClass: IRRITANT
• PackingGroup: III
• Hazardous Substances Data: 24131-32-6(Hazardous Substances Data)

Usage

Description

3,5-BIS(BENZYLOXY)BENZYL BROMIDE, with the molecular formula C21H19BrO2, is an organic compound characterized by the presence of two benzyloxy groups and a bromide atom attached to a benzyl moiety. It is widely recognized for its role in organic synthesis, particularly in the formation of carbon-carbon and carbon-heteroatom bonds, and is instrumental in palladium-catalyzed cross-coupling reactions and other chemical transformations.

Uses

Used in Organic Synthesis:
3,5-BIS(BENZYLOXY)BENZYL BROMIDE is used as a reagent for the formation of carbon-carbon and carbon-heteroatom bonds, which are crucial in constructing complex organic molecules and frameworks.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, 3,5-BIS(BENZYLOXY)BENZYL BROMIDE is used as a key building block for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Fine Chemicals Production:
3,5-BIS(BENZYLOXY)BENZYL BROMIDE is also utilized in the production of fine chemicals, where its unique structure and reactivity are harnessed to create specialty chemicals for various applications.
Used in Palladium-Catalyzed Cross-Coupling Reactions:
3,5-BIS(BENZYLOXY)BENZYL BROMIDE is employed as a reactant in palladium-catalyzed cross-coupling reactions, a significant method in modern organic chemistry for forming carbon-carbon bonds, which is essential for the synthesis of complex organic molecules and advanced materials.

InChI:InChI=1/C21H19BrO2/c22-14-19-11-20(23-15-17-7-3-1-4-8-17)13-21(12-19)24-16-18-9-5-2-6-10-18/h1-13H,14-16H2

Upstream product

• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 29654-55-5 5-(hydroxymethyl)benzene-1,3-diol 
• 28917-43-3 3,5-dibenzyloxybenzoic acid 
• 50513-72-9 (3,5-di-benzyloxy)benzoic acid benzyl ester 
• 99-10-5 3,5-Dihydroxybenzoic acid 
• 58605-10-0 methyl 3,5-bis(benzyloxy)benzoate 
• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 
• 80457-61-0 methanesulfonyl 3,5-dibenzyloxybenzyl alcohol 
• 24131-31-5 3,5-dibenzyloxybenzyl alcohol 

Downstream Products

• 440636-07-7 3-[4-(3,5-bis-benzyloxy-benzyloxy)-phenyl]-2-tert-butoxycarbonylamino-propionic acid methyl ester 
• 497103-48-7 4-[3,5-bis(benzyloxy)benzyloxy]pyridine-2,6-dicarboxylic acid dimethyl ester 
• 868784-34-3 1,3-bis-(3,5-bis-benzyloxy-benzyl)-3H-imidazol-1-ium; bromide 
• 1229034-26-7 C₂₇H₂₃NO₅ 
• 33617-49-1 diethyl <3,5-bis(benzyloxy)benzyl>phosphonate 
• 1432660-26-8 diethyl 2-benzyl-2-(3,5-bisbenzyloxybenzyl)malonate 
• 1432660-27-9 2-benzyl-2-(3,5-bisbenzyloxybenzyl)-1,3-propanediol 
• 1432660-30-4 1-(1,3-bisbenzyloxyphenyl)-3-phenylpropane 
• 1384118-93-7 C₆₀H₄₆O₆ 
• 1384118-90-4 C₆₆H₆₂O₆Si₂ 
• 1376686-91-7 C₃₉H₄₃N₃O₂Si₂ 
• 811473-55-9 1-azidomethyl-3,5-bis(benzyloxy)benzene 
• 1268341-78-1 4-(2-ethynylphenyl)but-3-ynyl 3,5-bis(3,5-bis(benzyloxy)benzyloxy)benzoate 
• 1268341-77-0 4-(2-(2-(trimethylsilyl)ethynyl)phenyl)but-3-ynyl 3,5-bis(3,5-bis(benzyloxy)benzyloxy)benzoate 

Relevant articles and documents

First example of a diazepinoporphyrazine with dendrimeric substituents

The synthesis and physicochemical properties of a novel diazepinoporphyrazine possessing G1-dendrimeric substituents are presented. Initially, diaminomaleonitrile was condensed with 1,3-bis-(4-hydroxyphenyl)-1,3-propanedione to give a novel 1,4-diazepine-

Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability

Cannabidiol is the nonpsychoactive natural component of C. sativa that has been shown to be neuroprotective in multiple animal models. Our interest is to advance a therapeutic candidate for the orphan indication hepatic encephalopathy (HE). HE is a serious neurological disorder that occurs in patients with cirrhosis or liver failure. Although cannabidiol is effective in models of HE, it has limitations in terms of safety and oral bioavailability. Herein, we describe a series of side chain modified resorcinols that were designed for greater hydrophilicity and "drug likeness", while varying hydrogen bond donors, acceptors, architecture, basicity, neutrality, acidity, and polar surface area within the pendent group. Our primary screen evaluated the ability of the test agents to prevent damage to hippocampal neurons induced by ammonium acetate and ethanol at clinically relevant concentrations. Notably, KLS-13019 was 50-fold more potent and >400-fold safer than cannabidiol and exhibited an in vitro profile consistent with improved oral bioavailability.

NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY

Pharmaceutical compositions of the invention include novel functionalized 1,3-benzenediols having a disease-modifying action in the treatment of hepatic encephalopathy and related conditions. Pharmaceutical compositions of the invention further include novel neuroprotective agents.